Phase II Trial of Sorafenib in Patients with Chemotherapy Refractory Metastatic Esophageal and Gastroesophageal (GE) Junction Cancer

PURPOSE: Vascular endothelial growth factor receptor (VEGFR2) directed therapies result in a modest survival benefit for patients with advanced esophageal and gastroesophageal (GE) junction cancer. Platelet-derived growth factor receptor (PDGFR) may contribute to escape from VEGFR2 inhibition. We ev...

Descripción completa

Detalles Bibliográficos
Autores principales: Janjigian, Yelena Y., Vakiani, Efsevia, Ku, Geoffrey Y., Herrera, Jessica M., Tang, Laura H., Bouvier, Nancy, Viale, Agnès, Socci, Nicholas D., Capanu, Marinela, Berger, Michael, Ilson, David H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4537304/
https://www.ncbi.nlm.nih.gov/pubmed/26275293
http://dx.doi.org/10.1371/journal.pone.0134731

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4537304/
https://www.ncbi.nlm.nih.gov/pubmed/26275293
http://dx.doi.org/10.1371/journal.pone.0134731

Ejemplares similares